A standardized protocol for autologous stromal vascular fraction therapy in refractory thin endometrium and a prospective single-arm clinical study Authors: TianLiu Peng, Shuo Yang, Lin Fu, Liang Liang, Fenting Liu, Yongyan Chen, Weisi Lian, Yang Yu, Rong Li Published: 2026 ABSTRACT BackgroundThin endometria are still a big obstacle in fertility treatments and often lead to poor pregnancy outcomes. Stromal vascular fraction (SVF) therapy has shown promise in the improvement of endometrial thickness. However, its preparation and treatment protocols lack standardization, and its efficacy and safety in assisted reproductive technology (ART) need to be further investigated.MethodsThrough the collaboration of plastic surgery, obstetrics and gynecology as well as Good Manufacturing Practice (GMP) laboratory teams, an efficient protocol was developed for the completion of liposuction, hysteroscopy, SVF preparation, quality control and intrauterine infusion on the same day of treatment. This single-center, prospective, self-controlled prospective cohort study was performed at Peking University Third Hospital. Eligible participants (aged 20–45) were patients who had an endometrial thickness of < 7 mm on the day of ovulation or endometrial transformation in hormone replacement cycles. The primary outcome was the proportion of patients whose endometrial thickness increased to 7 mm. All participants were followed up during the first three menstrual cycles after treatment via hospital follow-up visits and then by telephone for the next two years. All adverse events related to the operation were recorded. Outcomes, including menstrual volume, endometrial thickness, pregnancy rate and offspring health, were measured. This study was registered with Chinese Clinical Trial Registry (ChiCTR), ChiCTR2000035126.ResultsStandard SVF preparation and treatment procedures can be efficiently completed within six hours. From December 4, 2020 to August 5, 2022, 35 patients were treated with SVF intrauterine perfusion, and 30 were followed up after the intervention. Participants were aged 35.6 ± 3.85 on average. They had a mean body mass index (BMI) of 24.88 ± 2.05 kg/m2 and a mean pre-treatment endometrial thickness of 5.1 ± 0.94 mm. The SVF used for treating patients had a cell viability of over 90%. After SVF therapy, the mean endometrial thickness at three cycles after treatment was 5.8 ± 0.85 mm, 6.9 ± 1.33 mm and 6.8 ± 1.68 mm, respectively, with a significant increase compared with pre-treatment thickness (p < 0.05). At three months, 18 (51%) of 35 patients achieved an endometrial thickness of 7 mm or above. This increased to 21 (60%) patients two years later. Notably, 11 participants conceived, among whom six gave birth. No adverse events were reported.ConclusionsA streamlined and efficient protocol was established for SVF preparation and treatment, which ensured the effective patient management and consistent production of high-quality SVF. Autologous SVF intrauterine infusion is promising as a safe and effective therapeutic option for patients with refractory thin endometrium. The absence of adverse effects within this cohort over the two-year follow-up period indicates a good safety profile for SVF therapy.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s13287-026-05085-3. Introduction The sufficient thickness of endometria is usually considered a key determinant of successful embryo implantation. It plays a pivotal role in shaping fertility outcomes. Measured in the late follicular phase or on the day of progesterone conversion in hormone replacement cycles, an endometrial thickness below 7 mm is characterized as a thin endometrium. This characterization is supported by a number of studies. These studies affirm that an endometrial thickness below 7 mm is related to decreased implantation and ongoing pregnancy rates, even in assisted reproductive technology (ART) cycles [1–4]. Moreover, the condition of thin endometria potentially amplifies the risk of obstetric complications such as placenta previa, preterm labor and gestational hypertension, which endangers maternal and fetal prognosis [5–8]. The aetiological factors contributing to thin endometria are diverse and generally intricate. They encompass recurrent intrauterine procedures, infections and even idiopathic causes, which can result in refractory thin endometrium [9]. Regrettably, options for therapeutic intervention remain limited. As the most classical therapeutic approach, the hormonal strategy involves the dose adjustment of oestrogen to stimulate endometrial proliferation [10]. Despite probably contributing to the rectification of uterine cavity morphology, hysteroscopic surgery fails to promote endometrial growth, which thereby potentially facilitates the recurrence of intrauterine adhesions (IUAs) [11]. Other methods, including aspirin, sildenafil citrate, granulocyte-colony-stimulating factor (G-CSF), electrostimulation [12–17], etc., are aimed at improving blood supply and stimulating endometrial growth. Unfortunately, most patients’ endometria did not respond well to these treatments, and they are still faced with recurrent embryo transfer cancellations or implantation failure. Recently, cell therapy has appeared as a promising strategy for endometrium repair. The most common choice is mesenchymal stem cells (MSCs) derived from various tissues. These MSCs include bone marrow-derived MSCs (BMMSCs) [18–21], adipose-derived mesenchymal stromal cells (ASCs), umbilical cord-derived MSCs (UCMSCs) [22, 23], endometrial MSCs (eMSCs) [24], etc. Animal and clinical studies suggest that these cells repair endometria and increase the rate of embryo implantation and live births. Nevertheless, the preparation of stem cells calls for long periods of in-vitro culture and faces risks of contamination [25], genetic stability aberrations [26] and uncertain tumorigenicity [27]. Thus, the widespread use of stem cells in clinical practice remains controversial. Stromal vascular fraction (SVF) is a mixture of cells obtained from adipose tissue by enzymatic or mechanical methods. Unlike ASCs requiring prolonged in vitro culture, SVF is simpler and faster to prepare and has less risk of contamination. It contains ASCs, adipose progenitor cells, monocytes/macrophages, pericytes and endothelial cells [28]. SVF has been used for repairing injuries in a variety of systems, such as osteoarthritis, skin wounds, urology and cardiology [29–31]. It has also demonstrated efficacy in the treatment of endometrial injury. SVF increased vascular endothelial growth factor (VEGF) expression, enhanced angiogenesis and reduced endometrial fibrosis in a rat model of endometrial injury [32]. As for clinical research, five Asherman’s syndrome patients received uterine perfusion with SVF in 2020. All patients exhibited increased endometrial thickness after the intervention and proceeded with embryo transfer. One patient got pregnant after embryo transfer [33], which suggested the potential therapeutic effect of SVF in endometrial injury. Several clinical and animal studies have demonstrated that SVF therapy is safe and effective in other systems [34]. However, the application of SVF therapy in human endometria has primarily been limited to case reports or small-scale observational studies. In this study, patients with refractory thin endometrium who underwent the intrauterine infusion of SVF were enrolled, and a two-year prospective, self-controlled study was conducted to evaluate the safety and efficacy of this treatment. Methods Study design, ethics and participants A single-center, prospective self-controlled study was conducted in accordance with a previously published protocol available in BMJ Open [35]. From December 2020, patients were recruited through clinicians and by posting posters. They were treated and followed up at Peking University Third Hospital. The inclusion criteria for participants were as follows: (1) patients with a desire for pregnancy and an endometrial thickness of less than 7 mm on the day of ovulation or endometrial transformation in hormone replacement cycles (all of patients had previously undergone estrogen therapy without success); (2) patients aged between 20 and 45; (3) patients with a body mass index (BMI) of 22–29 kg/m2; and (4) patients with serum follicle-stimulating hormone (FSH) level below 15 IU/L (measured during the early follicular phase, specifically on days 2 to 4 of the menstrual cycle) or available frozen embryos. The exclusion criteria were as follows: (1) patients with a history of endometrial pathology diagnosed by hysteroscopy (excluding IUAs); (2) patients with uncontrolled systemic diseases and a positive result on diagnostic tests for infectious diseases; (3) patients or their first-degree relatives with suspected or confirmed malignancy; (4) patients abusing alcohol or drugs; or (5) patients refusing to provide informed consent or participate. All participants acted as their own controls. All participants received a single intrauterine infusion of fresh SVF. Following the SVF treatment, participants underwent clinical evaluation upon the onset of their next menstruation; if deemed eligible, they proceeded to an ART cycle. They were followed up in the hospital during the first three menstrual cycles after treatment and then by telephone for the next two years. Any adverse events associated with the operation were recorded. Outcomes, including menstrual volume, endometrial thickness, pregnancy rate and offspring health, were measured (Fig. 1A). Fig. 1Complete process and study flowchart. Complete process of SVF treatment and follow-up for thin endometria. Flow chart of the study. Among 35 patients undergoing SVF intrauterine perfusion, 30 completed the follow-up after the intervention. Three patients were excluded in light of the findings from hysteroscopy and pathological examination, which revealed other endometrial lesions. Two patients were lost to follow-up after treatment Complete process and study flowchart. Complete process of SVF treatment and follow-up for thin endometria. Flow chart of the study. Among 35 patients undergoing SVF intrauterine perfusion, 30 completed the follow-up after the intervention. Three patients were excluded in light of the findings from hysteroscopy and pathological examination, which revealed other endometrial lesions. Two patients were lost to follow-up after treatment This study was prospectively registered with Chinese Clinical Trial Registry (ChiCTR), ChiCTR2000035126. The protocol gained the approval of the Ethics Committee of Peking University Third Hospital (Title: Study on the Efficacy and Safety of Autologous Stromal Vascular Fraction in the Treatment of Thin Endometria, Approval Date: 2020-10-22, Reference No.: REC2020-165). Written informed consent was provided by all participants. Treatment day: hysteroscopy, liposuction, SVF preparation and intrauterine infusion therapy Step 1: Liposuction and hysteroscopic examination All patients received hysteroscopy and SVF infusion during the proliferative phase (on Days 5–14 of the menstrual cycle). After general anesthesia was administered to a patient, a hysteroscopic examination was performed to assess his intrauterine condition. After the hysteroscopy, the patient underwent liposuction, with 200–300 mL of abdominal fat extracted. The adipose tissue was preserved at 4–8 ℃and transferred to a Good Manufacturing Practice (GMP) standard laboratory for further processing. Step 2: SVF preparation and quality assessment For SVF preparation, the adipose tissue sample was transferred into 50 mL centrifuge tubes and washed with an equal volume of saline. Scissors and forceps were utilized to remove blood vessels and connective tissue from the surface of the adipose tissue. The tissue blocks were transferred into a 50 mL centrifuge tube, with a maximum of 10 mL per tube, and an equal volume of 0.1% collagenase II was added. The tube was placed into a benchtop incubator shaker set at 100 rpm and 37 ℃ for 40 min to digest. After complete digestion, 20 mL of saline was added to stop collagenase digestion. One-minute centrifugation was performed at 500 rpm (rotor radius: 16.5 cm, TX-200 Swinging Bucket, Multifuge™ X1Pro, Thermo Scientific ) to separate oil and digestion products into layers. The supernatant was discarded, and the lower solution was transferred through a 100 μm cell strainer into a new centrifuge tube to remove undigested adipose tissue. The filtered solution was subjected to 10-minute centrifugation at 2,000 rpm at room temperature. Saline was added to the centrifuge tube to a total volume of 50 mL. The centrifuge was set at 1,500 rpm for five-minute centrifugation at room temperature. The supernatant was discarded, and 50 mL saline was added to resuspend the cell pellet for a second wash. Five-minute centrifugation was performed again at 1,500 rpm at room temperature. The supernatant was discarded, and the washing procedure was repeated with 50 mL saline for a third wash. Finally, 10 µL of the cell suspension was taken into a 1.5 mL Eppendorf (EP) tube, and the suspension was diluted with 40 µL of saline. Quality assessment In this step, 10 µl of the SVF cell suspension was taken for cell counting and viability assessment, and Trypan Blue dye was added at a ratio of 1:1. Based on the counting results, the cell concentration was adjusted to 5–10 × 10⁷/mL. Under these conditions, the required volume of SVF is 2–3 mL when the therapeutic cell dosage is 10⁷-10⁸ cells. After the resuspension of the cell pellet in saline, a 1 mL aliquot of the SVF was collected for analyses, including mycoplasma detection, endotoxin and cell viability. All three assays required to be completed within two hours. Additional microbiological evaluations for bacterial, fungal and viral contaminants were performed within seven days (Supplementary Materials, Supplementary Table 1). Subsequently, flow cytometric analysis was conducted using a separate 1 mL SVF aliquot to characterize the immunophenotype. The SVF was transferred into a sterile vial, and an icebox maintained at 2–8 ℃ was used. The SVF can be released for the treatment of patients only after passing quality control. The remaining SVF was disposed of as medical waste as per established procedures. In vitro expansion culture of the SVF derived from adipose tissue was performed, and the properties of ASCs therein were characterized (Supplementary Materials, Supplementary Fig. 3). Step 3: SVF intrauterine infusion SVF (containing 10⁷-10⁸ cells, approximately 3 mL) was transplanted into the uterine cavity using an embryo transfer catheter. Before SVF infusion, a small cannula was applied to suction out any residual distending fluid. Then, the SVF was instilled into the uterine cavity slowly and gently for over three minutes. A small amount of backflow was noted. After that, the patients were kept in a supine position for 30 min. Assessments and follow-up Detailed follow-up procedures and outcome measurements can be found in the previously published protocol [35] and Supplementary Materials. Patients received five in-hospital follow-ups within the first three months after treatment and continued telephone follow-ups for two years. On Day 1 after treatment, the first follow-up involved intrauterine fluid aspiration, the recording of physical condition, and adverse events. During Week 1 after treatment, the second follow-up included a medical history inquiry, physical examination, the assessment of persistent health issues, vital signs and transvaginal ultrasound for the measurement of endometrial thickness and morphology (The morphology is classified according to the ultrasound grading system for endometrial echogenicity and pattern [36]: A: The endometrium exhibits a multilayered structure. Outer layers and the midline appear hyperechoic, and the inner layer appears hypoechoic and is known as the “triple-line pattern”; B: The endometrium is of intermediate type and isoechoic with the myometrium, with an indistinct or absent central echo line; C: The endometrium displays a uniform, hyperechoic pattern, without a distinct central echo line. Blood tests for inflammatory and biochemical markers, and adverse event reporting are needed. Subsequent follow-ups on Days 14–21 of the first, second and third menstrual cycles, respectively, assessed medical history, menstrual changes and endometrial thickness via transvaginal ultrasound. Adverse events were monitored in each follow-up by recording procedure-related complications (e.g., anesthesia-related events, uterine perforation, hemorrhage and infection) and post-transplantation symptoms (e.g., rash, abdominal pain and emerging gynecological changes). The third follow-up also included hysteroscopy, if clinically indicated, to evaluate intrauterine morphology and endometrial histology. During the two-year follow-up period, the participants could attempt natural conception or initiate in vitro fertilization (IVF) treatment. Pregnancy outcomes such as clinical pregnancy, miscarriage and live birth rates, along with offspring development, were tracked via telephone at an interval of six months for two years. Outcomes The primary outcome was the proportion of patients whose endometrial thickness increased to 7 mm. This was evaluated as the thickest part in the longitudinal axis of the uterus (endometrial thickness) by transvaginal ultrasound in a blinded fashion. Professional ultrasound physicians (unaware of patient participation in SVF treatment) measured endometrial thickness at the timepoints: during the late follicular phase (approaching the day of ovulation) in natural cycles, or on the day of progesterone administration in hormone replacement cycles, over the first three menstrual cycles after treatment. Efficacy rate (%) = the number of patients with increased endometrial thickness after treatment/the total number of included patients × 100%. Secondary outcomes included changes in menstrual status (the increased menstrual flow was assessed subjectively by patients through self-evaluations, comparing their post-treatment menstrual volume with their typical basal menstrual flow prior to intervention) and pregnancy-associated outcomes, such as clinical and biochemical pregnancies, ongoing pregnancies, miscarriages and live births. Adverse events, including rashes, bleeding, infections, and complications from liposuction, SVF transplantation or hysteroscopy (e.g., uterine perforation, haemorrhage, adhesion and infection), were meticulously documented to guarantee comprehensive safety evaluation. Statistical analysis Reportedly, the effectiveness rate of estrogen therapy for refractory thin endometrium is 38% [37]. The pretest data of this study reported a 70% effective rate of SVF treatment. Accordingly, the null hypothesis posits that the proportion of responders is 38% (H₀: p = 0.38), whereas the alternative hypothesis asserts that this proportion exceeds 38% (H₁: p > 0.38). The anticipated proportion is 70% under the alternative hypothesis. With a one-sided significance level of α = 0.05 and a power (1-β) of 95%, N = 24 patients were obtained. Considering that the missing data were below 20%, the final sample size needed in the present study was N = 30. Quantitative data were expressed as mean ± standard deviation (SD). Repeated measures analysis of variance (ANOVA) was used for comparing the quantitative data of primary outcomes. Categorical data for secondary outcomes were presented as percentages (%). Post-hoc analyses: The Shapiro-Wilk test was used to assess the normality of the SVF immunophenotype data, with the distribution visualized via Quantile-Quantile (Q-Q) plots. The Shapiro-Wilk test provided a W statistic and a p-value to determine whether the data significantly deviated from a normal distribution. Statistical significance was defined to be a p-value below 0.05. Statistics and plotting were performed using GraphPad Prism 9.5. Results Participant characteristics Between December 4, 2020 and August 5, 2022, 35 patients were treated with the intrauterine perfusion of SVF at Peking University Third Hospital, and 30 were followed up after the intervention. Three patients were excluded after hysteroscopy and pathological examination with a diagnosis of endometrial lesion, and two declined to participate in the follow-up visit. Among the three patients, two were diagnosed with endometrial tuberculosis, and one was diagnosed with endometrial hyperplasia (without atypia). The participants had a mean age of 35.6 ± 3.85, a BMI of 24.88 ± 2.05 kg/m2 and a mean pre-treatment endometrial thickness of 5.1 ± 0.94 mm. All these patients had experienced no less than two instances of unsuccessful hormone therapy. In total, 20 patients had IUA of varying grades (I-IV) according to the guidelines of European Society of Gynecological Endoscopy [38] (Table 1). Due to the Coronavirus Disease 2019 (COVID-19) pandemic, three patients from remote areas were unable to return to the hospital in time to complete the examination and followed up by telephone after the examination at the hospital in their locality. Table 1Clinical characteristics of patientsCharacteristicPatient, n = 30Age, mean ± SD, years35.6 ± 3.85BMI, mean ± SD, kg/m224.88 ± 2.05History IUA gradeNo IUA: 10(33%)I: 7(23%)II: 6(20%)III: 6(20%)IV: 1 (3%) Table 1Clinical characteristics of patientsCharacteristicPatient, n = 30Age, mean ± SD, years35.6 ± 3.85BMI, mean ± SD, kg/m224.88 ± 2.05History IUA gradeNo IUA: 10(33%)I: 7(23%)II: 6(20%)III: 6(20%)IV: 1 (3%) Clinical characteristics of patients No IUA: 10(33%) I: 7(23%) II: 6(20%) III: 6(20%) IV: 1 (3%) SVF characteristics Adipose tissue from all patients was successfully processed into SVF meeting quality standards. The SVF used for patient treatment had a cell viability of more than 90%. Flow cytometry results from 16 SVF samples were analyzed. It was found that the percentage distribution of immunophenotypes in each SVF group was similar (Fig. 2). Additionally, the proportion of each immunophenotype followed a normal distribution, which indicated that the SVF preparation protocol ensured consistent immunophenotypes (Table 2). Meanwhile, multicolor co-staining was employed to determine the main cellular composition in SVF. In the SVF suspension, stromal cells accounted for around 50%, and endothelial ones took up about 18% (as shown in Fig. 2B and E). By selecting cluster of differentiation 34 (CD34)+CD45- cells and labelling them with CD90 and CD73, it was discovered that ASCs constituted over 80% of stromal cells. Release testing was completed within two hours after preparation, and standard testing was finished within seven days, with all SVF samples testing negative. Fig. 2Immunophenotypes and cell types of SVF. A Distribution of immunophenotypes in 16 SVF samples. B Flow cytometric analysis of co-staining for CD34 and CD45 in SVF. The CD34 + CD45- population represents stromal cells and comprises approximately 50.72% of cells. C, D From the CD34 + CD45- cells, 92.86% are CD90+, and 85.95% are CD73+. They are markers characteristic of ASCs, which indicate their proportion within stromal cells. E Co-staining of CD34 and CD31. CD34 + CD31- cells are stromal cells (~ 52.60%). CD34 + CD31+ cells are endothelial cells and account for about 18.25% Immunophenotypes and cell types of SVF. A Distribution of immunophenotypes in 16 SVF samples. B Flow cytometric analysis of co-staining for CD34 and CD45 in SVF. The CD34 + CD45- population represents stromal cells and comprises approximately 50.72% of cells. C, D From the CD34 + CD45- cells, 92.86% are CD90+, and 85.95% are CD73+. They are markers characteristic of ASCs, which indicate their proportion within stromal cells. E Co-staining of CD34 and CD31. CD34 + CD31- cells are stromal cells (~ 52.60%). CD34 + CD31+ cells are endothelial cells and account for about 18.25% Table 2Normality test results with descriptive statistics for immunophenotyp of SVFMarkerMean (%)Standard deviationWp-valueCD3470.817.3486021060.9659343360.769232869CD3121.156.4227002370.889774740.055248208CD4526.625.0675937750.9450179340.415073097CD11b15.623.9001553390.9493739010.479833871CD4478.755.377898560.912791610.129081681CD9077.476.697534870.9368220570.311891973CD1059.235.7726181240.9117114540.124005854CD7355.546.3047430560.9594339730.65152806CD1378.194.2434097430.9710845950.855858743CD2990.503.1234670240.9613856080.687006176The Shapiro-Wilk test assessed whether the data of each marker followed a normal distribution. P-value > 0.05 suggested that the data did not significantly deviate from normality. The W statistic indicated the goodness of fit, with values closer to 1 reflecting a distribution closer to normal Table 2Normality test results with descriptive statistics for immunophenotyp of SVFMarkerMean (%)Standard deviationWp-valueCD3470.817.3486021060.9659343360.769232869CD3121.156.4227002370.889774740.055248208CD4526.625.0675937750.9450179340.415073097CD11b15.623.9001553390.9493739010.479833871CD4478.755.377898560.912791610.129081681CD9077.476.697534870.9368220570.311891973CD1059.235.7726181240.9117114540.124005854CD7355.546.3047430560.9594339730.65152806CD1378.194.2434097430.9710845950.855858743CD2990.503.1234670240.9613856080.687006176The Shapiro-Wilk test assessed whether the data of each marker followed a normal distribution. P-value > 0.05 suggested that the data did not significantly deviate from normality. The W statistic indicated the goodness of fit, with values closer to 1 reflecting a distribution closer to normal Normality test results with descriptive statistics for immunophenotyp of SVF The Shapiro-Wilk test assessed whether the data of each marker followed a normal distribution. P-value > 0.05 suggested that the data did not significantly deviate from normality. The W statistic indicated the goodness of fit, with values closer to 1 reflecting a distribution closer to normal Primary outcome of the SVF therapy The post-treatment mean thickness at three cycles was 5.8 ± 0.85 mm, 6.9 ± 1.33 mm and 6.8 ± 1.68 mm, respectively, with a significant increase compared with the pre-treatment thickness (Fig. 3; p < 0.05) embodied in the 95% confidence intervals for change, which are above zero (Table 3; Fig. 4; Supplementary Materials, Supplementary Fig. 2). A total of 18 patients achieved an endometrial thickness of 7 mm within three menstrual cycles after treatment. After the first three cycles, a follow-up was completed by telephone, and data on endometrial thickness were only recorded with definitive medical documentation. Finally, 21 patients achieved an endometrial thickness of 7 mm within two years (Supplementary Materials, Supplementary Table 2). The efficacy rate, calculated as the percentage of patients whose post-treatment endometrial thickness increased to 7 mm relative to the total number of included patients, was 60% (21/35 patients). The transvaginal ultrasound results showed an improvement in endometrial thickness. Regarding the morphology, no patients presented with a grade C endometrium, and most patients developed a grade A or B endometrium, which indicated desirable endometrial morphology. However, some patients could not be graded due to excessively thin endometria. Of note, the endometrial morphology in patients with thin endometria is more difficult to grade under ultrasound examination compared to that in patients with healthy endometria. Therefore, the morphological assessment of endometria may involve subjective errors (Fig. 4, Supplementary Table 2). Fig. 3Endometrial thickness before and after therapy. A Significant increase in endometrial thickness at three cycles after treatment compared to before treatment. *p < 0.05 (B) Trend of changes in endometrial thickness Endometrial thickness before and after therapy. A Significant increase in endometrial thickness at three cycles after treatment compared to before treatment. *p < 0.05 (B) Trend of changes in endometrial thickness Table 3Primary outcomeEndometrium thicknessPre-treatmentPost-treatment1Post-treatment2Post-treatment3Mean ± SD, mm5.18 ± 0.945.8 ± 0.856.9 ± 1.336.8 ± 1.68p-value–< 0.001< 0.0001< 0.001Mean Diff.0.61331.681.66595.00% CI of diff.(0.06157, 1.165)(0.9473, 2.413)(0.7632, 2.566) Table 3Primary outcomeEndometrium thicknessPre-treatmentPost-treatment1Post-treatment2Post-treatment3Mean ± SD, mm5.18 ± 0.945.8 ± 0.856.9 ± 1.336.8 ± 1.68p-value–< 0.001< 0.0001< 0.001Mean Diff.0.61331.681.66595.00% CI of diff.(0.06157, 1.165)(0.9473, 2.413)(0.7632, 2.566) Primary outcome Fig. 4Transvaginal ultrasonography of the uterus before and after SVF treatment Transvaginal ultrasonography of the uterus before and after SVF treatment Secondary outcomes of the SVF therapy The treatment led to an increase in the menstrual flow of seven patients, with a mean percentage change of 23% (two within the first three cycles and five thereafter). A total of 26 patients underwent embryo transfer, which yielded an embryo transfer rate of 7%. In addition, 11 patients conceived three to 19 months after treatment, two of whom conceived naturally and the remaining nine conceived with the help of ART (see Supplementary Materials and Supplementary Table 1 for details). Biochemical pregnancy (a level of serum human chorionic gonadotropin higher than 25 mIU/ml) was found in 11 patients (37%). Clinical pregnancy (viable gestational sac) was noticed in eight patients (27%). Ongoing pregnancy (pregnancy beyond 12 weeks) was observed in six patients (20%). Six patients gave birth to live neonates via vaginal delivery or cesarean Sect. (20%). Four patients miscarried (13%) (Table 4). Biochemical pregnancy loss was noted in one patient. Ectopic pregnancy was observed in one patient. One patient had an embryonic abortion at eight weeks of pregnancy. One patient experienced embryonic demise at nine weeks of gestation. The cytogenetic analysis of chorionic villi revealed trisomy 22. Table 4Secondary outcomesMenstrual recovery rateBiochemical pregnancy rateClinical pregnancy rateOngoing pregnancy rateMiscarriage rateLive birth rateAdverse events rate23% (7/30)37% (11/30)27% (8/30)20% (6/30)13% (4/30)20% (6/30)0% (0/30) Table 4Secondary outcomesMenstrual recovery rateBiochemical pregnancy rateClinical pregnancy rateOngoing pregnancy rateMiscarriage rateLive birth rateAdverse events rate23% (7/30)37% (11/30)27% (8/30)20% (6/30)13% (4/30)20% (6/30)0% (0/30) Secondary outcomes Adverse events and safety assessment No adverse events linked to liposuction, such as dermatitis, haemorrhage, infection and anaesthesia complications, were detected during or after the procedure. All participants tolerated the autologous SVF transplantation and hysteroscopy well. They did not report any abdominal pain, allergic reactions or other undesirable outcomes. Serum levels of alanine aminotransferase (ALT), C-reactive protein (CRP) and phosphocreatine kinase (PCK) were measured 7–10 days after SVF transplantation. They were within normal ranges (CRP ≤ 0.8 mg/dL, ALT 7–40 U/L and PCK 26–140 U/L) for a majority of participants. Only one participant experienced an elevation in the level of CRP (1.94 mg/dL), but did not feel uncomfortable. The rate of adverse reactions was 0%. Discussion This single-center, single-arm, prospective cohort study is the first registered clinical study to evaluate whether SVF therapy is safe and effective in treating thin endometria. In total, 35 patients diagnosed with thin endometrium got involved in the study. Their adipose tissue was extracted to produce autologous SVF, which was then infused into the uterine cavity. Hospital follow-ups were conducted after three menstrual cycles, with long-term monitoring via telephone over a two-year period. Two years after treatment, 21 patients achieved an endometrial thickness of at least 7 mm; seven patients reported increased menstrual flow; 11 patients conceived, two of whom naturally conceived and nine conceived through ART, which resulted in six live births. Importantly, no adverse events were reported during the follow-up period. Patients with refractory thin endometrium typically have a history of endometrial injury, such as inflammatory conditions and multiple uterine surgeries. These factors may irreversibly damage the basal layer of the endometrium and blood vessels. The pathology of thin endometria has been described as vascular dysplasia, high flow impedance, poor glandular epithelial growth and reduced VEGF expression [39]. Recent studies using two single-cell sequencing techniques have uncovered signs of collagen deposition in perivascular cells in the endometrium. They have also revealed the senescence of endothelial cells, the reduction of endometrial immune cells like macrophages and natural killer (NK) cells, and the aberrant communication of epithelial-stromal cells that results in abnormal endometrial growth [40]. For refractory thin endometrium, commonly used oestrogen therapy is hardly effective and excessive hormone therapy can carry the risk of side effects and tumorigenesis. Whether other types of treatment are effective for refractory thin endometrium remains highly controversial. SVF is a multicellular mixture of cells derived from adipose tissue. It includes various types of stem cells, including endothelial progenitor cells and adipose-derived stromal cells from adipose tissue, as well as hematopoietic stem cells from blood [28]. Moreover, SVF contains a variety of other cells, including monocytes, macrophages, pericytes, endothelial cells, etc [41]. It has potential for promoting angiogenesis, with up to 60–70% of CD34 + cells. These CD34 + cells serve as markers for not only adipose precursor cells but also the vascular endothelial cell/hematopoietic microenvironment [42]. In a model of wound healing in mice, SVF secreted more epithelialization and chemotactic growth factors in comparison to ASCs. Furthermore, SVF exhibits a stronger ability in promoting capillary angiogenesis and faster wound healing, as reported previously [43]. In a model of hindlimb ischemia, SVF demonstrated greater potential for angiogenesis compared with ASCs [44]. In addition to its pro-angiogenic effects, SVF contains multiple growth factors, including epidermal growth factor (EGF) and transforming growth factor-β (TGF-β1), promoting cell proliferation and migration, which facilitates the healing of chronic wounds [45]. Apart from its pro-angiogenic effects, SVF exhibits immunomodulatory properties, inducing an anti-inflammatory response. It promotes an increase in M2 macrophages and regulatory T cells (Tregs), which relieves multiple sclerosis [46]. Currently, the preparation of SVF can be categorized into two methods: non-enzymatic and enzymatic, producing tissue-like and cellular-derived SVFs (tSVF and cSVF), respectively. Both types of SVF have their own characteristics. The enzymatic method requires using enzymes and takes more time. However, it yields cSVF, which provides numerous free cell suspensions. In contrast, tSVF obtained through mechanical separation not only retains a substantial amount of extracellular matrix (ECM) and cells but also calls for shorter preparation time. The ECM is rich in growth factors contributing to improved cell survival and supporting regeneration [28, 47]. Notwithstanding many advantages of tSVF, cSVF was chosen in this study. The primary reason is that the patients selected in this study have thin endometria, and most of them also suffer from IUAs. These adhesions are caused by the excessive deposition of ECM owing to inadequate repair after endometrial injury, which results in endometrial fibrosis [48, 49]. Given that tSVF contains a great amount of active ECM, attention had to be paid to the potential risk of exacerbating endometrial fibrosis. Hence, cSVF, which has the ECM removed and contains countless free cells, was selected for intrauterine infusion therapy. Moreover, the modified enzymatic method in this study does not require additional equipment, increasing costs and allowing SVF preparation to be completed within two hours. After preparation, the SVF was followed immediately by a comprehensive quality control protocol, including assessments of cell viability, quantity, composition and microbial contamination, all of which were completed within two hours. Beyond that, the cSVF in this study achieved over 90% high viability and 50% stromal cells compared with the cSVF obtained through other enzymatic methods [50]. In this study, over 90% of the patients were observed to experience endometrial growth in the first three months of treatment, which indicated the significant short-term effect of SVF on endometrial growth. It should be noted that all patients receiving SVF treatment in this cohort had fertility desires and subsequently attempted natural conception or received ART treatments. During the two-year follow-up period, physicians evaluated 26 patients meeting the criteria for embryo transfer on the basis of their endometrial condition. Given that all enrolled patients had an active desire to conceive, they underwent ovulation induction or artificial cycles to prepare for embryo transfer, which inherently involved exogenous hormone supplementation. Eventually, 11 patients became pregnant, including some cases of spontaneous conception that occurred while they were undergoing IVF treatments. A substantial proportion of these patients had a history of miscarriages and had undergone repeated intrauterine procedures, such as dilation and curettage (D&C) or hysteroscopy. Furthermore, they had demonstrated poor responses to conventional hormone therapies prior to the SVF intervention, indicating that SVF treatment effectively improves endometrial sensitivity to hormones. Furthermore, the occurrence of spontaneous pregnancies suggests that SVF intrinsically restored the endometrial microenvironment and hormone responsiveness, rather than the outcomes being solely driven by exogenous hormones. This demonstrated that SVF may have positive long-term effects on reproductive outcomes. Notably, successful embryo implantation and pregnancy do not depend solely on endometrial thickness. Thin endometria or endometrial adhesions normally result from fibrosis or long-term inadequate blood supply. Despite promoting endometrial proliferation, cell therapy might not sufficiently repair the endometrium to ideal implantation conditions in the short term. SVF is an abundant source of adipose-derived mesenchymal stem cells. The surface markers of SVF cells greatly resemble those of MSCs [51]. The stromal cells in the endometrium make up the largest proportion of the cell population, express surface markers of MSCs and exhibit their multipotency [52]. In view of this, some cells of SVF are likely to be transformed into endometrial stromal cells. Further evidence suggests that tissue-derived stem cells can exert an influence on endometrial cell transformation. Taylor found human leucocyte antigen (HLA)-mismatched donor cells in the endometria of bone marrow transplant recipients. This provided the first evidence that non-uterine cells could regenerate into endometrial tissue [53]. A recent study using umbilical cord MSCs for treating the uterine adhesions of rabbits noted that MSCs could transform into epithelial cells, fibroblasts and macrophages [54]. In summary, whether it promotes angiogenesis, anti-inflammation or cellular transformation, the mechanism of endometrium repair by SVF needs more research. In conclusion, this study demonstrates the safety and effectiveness of SVF in treating thin endometria. It comprises the largest patient cohort among similar studies. The use of autologous SVF obviates the risk of allogeneic rejection. The simple production of autologous SVF avoids the need for long-term in vitro culture, which thus minimizes the risk of microbial infection. By improving the microenvironment of refractory thin endometrium, SVF treatment can reduce the repeated cancellation of embryo transfer cycles caused by endometrial factors, which significantly alleviates the financial and psychological burdens on patients. While advocating the therapeutic use of SVF for managing thin endometria, this research highlights the potential of SVF treatment for thin endometria. Due to the presence of uncontrollable confounding variables, the inherent limitations of self-controlled studies and the relatively small sample size, however, it is very urgent to conduct more rigorous clinical research to validate the findings. More than that, advancing the understanding through mechanism research, optimizing protocols and improving treatment outcomes are critical steps forward. Consequently, more expansive research in this field is necessary to fully ascertain the benefits of SVF and refine its application in reproductive medicine. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1.